Pharmacogenomic approaches in the treatment of breast cancer by tamoxifen

被引：0

作者：

Ameen, Sidra ^{[1
]}

Qadir, Muhammad Imran ^{[1
]}

Ahmad, Bashir ^{[2
]}

机构：

[1] GC Univ, Coll Pharm, Faisalabad, Pakistan

[2] Bahauddin Zakariya Univ, Fac Pharm, Multan, Pakistan

来源：

PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES | 2012年 / 25卷 / 02期

关键词：

Breast cancer; tamoxifen; pharmacogenomics; ADVERSE DRUG-REACTIONS; CYP2D6; POLYMORPHISMS; ENDOCRINE THERAPY; CLINICAL-OUTCOMES; ESTROGEN-RECEPTOR; POTENTIAL ROLE; METABOLISM; GENOTYPE; IMPACT; RISK;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Breast cancer (BC) is a highly diverse complaint rather than sole disease consisting of several markers linked to typical features of tissues, medical assessment and reaction to treatment. Mutation in RAS/MEK/ERK and P13K-AKT-mTOR pathway is involved in pathogenesis of BC. Application of pharmacogenomics will lead to individualization of therapy, which is totally contrast to nowadays clinical practice, in which drug's effects are studied on large group of patient regardless of their genetic based difference. The genetic differences in persons affect the therapeutic action and concentration of Tamoxifen in each individual. Therefore, it is, concluded to choose best drug regimen for each patient on individual basis and to circumvent the patient by toxic effect of drug.

引用

页码：469 / 476

页数：8

共 68 条

[1] CYP2D6 polymorphisms and tamoxifen: therapeutic perspectives in the management of hormonodependent breast cancer patients [J].